CYBIN CEO Michael Halstead will participate in a fireside chat at the Cantor Global Healthcare Conference on September 11, with a live webcast and replay available. The event gives investors direct access to management while CYBIN develops HLP003 in Phase 3 and HLP004 in Phase 2 clinical development.

Key Highlights

  • Helus Pharma is developing HLP003 in Phase 3 and HLP004 in Phase 2 clinical development.
  • Helus Pharma’s CEO will represent the company in a fireside chat at the Cantor Conference in New York City, taking place September 9 through September 11, 2026.
  • The event will be webcast live, with registration available, and a replay will be posted through Helus Pharma’s Investor relations events and presentations page.
  • HLP004 is in Phase 2 clinical development for generalized anxiety disorder, while regulators have not evaluated claims concerning NSAs, HLP003, or HLP004.

The event will be webcast live, and a replay will be available through Helus Pharma’s investor relations events and presentations page.

CEO Appearance Set for Cantor Conference

The conference is taking place in New York City from September 9 through September 11, 2026. Helus Pharma said its chief executive will represent the Business during the fireside chat, with registration available for the webcast. Helus Pharma is the commercial operating name of CYBIN INC. (NASDAQ: HELP) The clinical-stage pharmaceutical company is developing proprietary novel serotonergic agonists, or NSAs, described as synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. HLP004 is in Phase 2 clinical development for generalized anxiety disorder. The release states that regulators have not evaluated claims concerning NSAs, HLP003 or HLP004, and that the products’ efficacy has not been confirmed by approved research.